| Literature DB >> 26225952 |
Jiang-Tao Zhou1,2, Chen-Yang Li3, Chun-Hua Wang4,5, Yue-Fei Wang6, Xiao-Dong Wang7, Hong-Tao Wang8, Yan Zhu9,10, Miao-Miao Jiang11,12, Xiu-Mei Gao13.
Abstract
In the present study, two new phenolic compounds 1 and 11, a pair of lignan isomers 12 and 13 with their absolute configurations established for the first time, were isolated from the ethanol extract of the roots of Rhodiola crenulata, together with 13 known phenolic compounds, and their structures were elucidated via NMR, HRESIMS, UV, IR and CD analyses. All the isolated compounds were evaluated for their in vitro antioxidant activities using the 2,2-diphenyl-1-picryhydrazyl (DPPH) and 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging assays. Ten of them exhibited significant antioxidant activities compared to ascorbic acid. Furthermore, the inducibilities of the isolated compounds to IFN-γ production were also assessed. Compounds 1, 8, 9, 12, 13, 14 and 15 could moderately stimulate IFN-γ expression.Entities:
Keywords: IFN-γ production; Rhodiola crenulata; antioxidant activity; immunomodulatory effect; phenol
Mesh:
Substances:
Year: 2015 PMID: 26225952 PMCID: PMC6332023 DOI: 10.3390/molecules200813725
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
1H-NMR and 13C-NMR data of compounds 1, 2 and 11–13 (400 MHz and 100 MHz, DMSO-d6, δ in ppm, J in Hz).
| No. | 1 | 2 | 11 | 12 | 13 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| δH | δC | δH | δC | δH | δC | δH | δC | δH | δC | |
| 1 | 125.5 | 131.8 | 127.7 | 127.6 | ||||||
| 2 | 7.33 (d, 2.0) | 111.2 | 147.6 | 6.79 (d, 1.2) | 114.0 | 7.01 (d, 1.8) | 112.2 | 7.07 (s) | 112.2 | |
| 3 | 149.5 | 135.9 | 147.4 | 148.1 | 148.3 | |||||
| 4 | 148.0 | 176.9 | 145.4 | 147.6 | 147.9 | |||||
| 5 | 6.80 (d, 8.2) | 115.5 | 152.7 | 6.74 a | 115.8 | 6.80 (d, 8.0) | 115.8 | 6.84 a | 115.5 | |
| 6 | 7.12 (dd, 8.2, 2.0) | 123.1 | 6.56 (s) | 95.4 | 6.64 (dd, 8.2, 1.8) | 117.3 | 6.85 (dd, 8.0, 1.8) | 121.0 | 6.85 a | 120.0 |
| 7 | 7.55 (d, 16.0) | 145.0 | 154.0 | 5.07 (d, 3.6) | 83.3 | 4.95 (d, 7.8) | 76.6 | 4.90 (d, 7.8) | 76.5 | |
| 8 | 6.47 (d, 16.0) | 114.4 | 126.4 | 3.70 (dd, 9.2, 3.8) | 53.0 | 4.20 (m) | 78.4 | 4.16 (m) | 78.5 | |
| 9 | 166.7 | 144.2 | 177.7 | 3.55 (d, 11.6) 3.35 a | 60.6 | 3.53 (d, 10.2) 3.35 (dd, 12.0, 4.2) | 60.6 | |||
| 10 | 103.8 | |||||||||
| 1′ | 173.3 | 122.3 | 131.0 | 128.2 | 130.5 | |||||
| 2′ | 2.33 (t, 7.4) | 33.1 | 8.14 (d, 8.8) | 130.2 | 6.99 (d, 1.2) | 111.1 | 7.30 (d, 2.0) | 116.9 | 7.05 (d, 2.0) | 115.9 |
| 3′ | 1.58 (m) | 24.1 | 6.94 (d, 8.8) | 115.9 | 148.2 | 144.3 | 144.4 | |||
| 4′ | 1.37 (m) | 25.0 | 159.8 | 145.7 | 146.1 | 143.8 | ||||
| 5′ | 1.64 (m) | 27.9 | 6.94 (d, 8.8) | 115.9 | 6.81 a | 115.9 | 6.94 (d, 8.0) | 117.6 | 6.87 (d, 8.0) | 117.3 |
| 6′ | 4.12 (t, 6.6) | 63.5 | 8.14 (d, 8.8) | 130.2 | 6.85 (dd, 8.2, 1.8) | 119.5 | 7.21 (dd, 8.0, 2.0) | 122.1 | 7.00 (dd, 8.0, 1.8) | 121.6 |
| 7′ | 5.39 (d, 3.6) | 85.4 | 7.52 (d, 16.0) | 143.9 | 7.12 (d, 15.8) | 136.6 | ||||
| 8′ | 3.28 (m) | 49.3 | 6.38 (d, 16.0) | 117.7 | 6.29 (d, 15.8) | 127.6 | ||||
| 9′ | 4.14 (dd, 9.2, 7.2) 3.95 (dd, 9.2, 4.0) | 72.5 | 168.3 | 171.2 | ||||||
| 3-OCH3 | 3.83 (s) | 55.7 | 3.78 (s) | 56.1 | 3.76 (s) | 56.2 | ||||
| 5-OCH3 | 3.91 (s) | 56.8 | ||||||||
| 1′-OCH3 | 3.59 (s) | 51.2 | ||||||||
| 3′-OCH3 | 3.79 (s) | 56.2 | ||||||||
a Overlapped signals are reported without designating multiplicity.
Figure 1Chemical structures of compounds 1–17.
Figure 2Key HMBC or NOESY correlations of compounds 1, 2 and 11–13.
Figure 3CD and UV spectra of compounds 12 (A) and 13 (B), where the arrow denotes the electronic transition dipole of the chromophores. (−) means the two chromophores should be oriented counterclockwise in space; (+) means the two chromophores should be oriented clockwise in space.
The IC50 values in μM of antioxidant activities of 1–17 (n = 3).
| Compounds | DPPH IC50 (μM) a | ABTS IC50 (μM) a |
|---|---|---|
| >500 b | >500 | |
| 114.3 ± 4.4 | 87.0 ± 7.9 | |
| 73.8 ± 2.9 | 129.8 ± 12.3 | |
| 91.6 ± 1.4 | 125.4 ± 9.8 | |
| 94.3 ± 2.3 | 123.9 ± 10.4 | |
| 83.0 ± 3.5 | 123.7 ± 12.8 | |
| 104.7 ± 1.8 | 63.7 ± 8.5 | |
| 96.5 ± 2.3 | 53.1 ± 4.8 | |
| 260.5 ± 36.4 | 320.2 ± 22.6 | |
| 64.1 ± 3.3 | 110.8 ± 10.7 | |
| >500 | >500 | |
| >500 | >500 | |
| >500 | >500 | |
| 227.1 ± 33.9 | 160.2 ± 8.8 | |
| >500 | >500 | |
| 52.8 ± 3.3 | 50.0 ± 4.9 | |
| 79.5 ± 1.7 | 65.0 ± 3.9 | |
| 88.6 ± 1.9 | 89.8 ± 6.8 |
a Data were represented as mean ± SD; b The IC50 value of sample is higher than 500 μM.
Figure 4IFN-γ production by spleen lymphocyte cells treated with compounds 1–17. Valus are means ± S.E.M., n = 3; * p < 0.05; ** p < 0.01; *** p < 0.005.
Figure 5Cell viability of mouse spleen lymphocyte cells after 48 h treatment by 100 μM concentration of compounds 1–17 using CCK-8 assay (data points represent the mean ± S.D., n = 3).